InflaRx (IFRX) Cash from Financing Activities (2016 - 2026)
InflaRx (IFRX) posted Cash from Financing Activities of -$87443.0 for Q1 2026, down 101.16% sequentially from $7.6 million in Q4 2025, and down 100.31% YoY from $28.4 million in Q1 2025.
InflaRx (IFRX) Cash from Financing Activities (2016 - 2026) Analysis & Trends
InflaRx has reported Cash from Financing Activities for 11 years, with the latest figure at -$87443.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 100.31% year-over-year to -$87443.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 million (down 74.9% YoY) and the FY2025 annual result came in at $37.6 million, up 8899.44% from the prior year.
- Cash from Financing Activities declined to -$87443.0 in Q1 2026 per IFRX's latest filing, from $7.6 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $57.9 million in Q2 2023 and troughed at -$115600.7 in Q2 2024.
- A 5-year average of $5.6 million and a median of -$93107.7 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities surged 59562.31% in 2023, then sank 387.22% in 2024.
- Over 5 years, Cash from Financing Activities stood at $2.3 million in 2022, then slumped by 104.53% to -$102107.8 in 2023, then jumped by 808.08% to $723002.0 in 2024, then soared by 945.21% to $7.6 million in 2025, then plunged by 101.16% to -$87443.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$87443.0, $7.6 million, and -$99314.7 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | 138.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -87,442.99 |
| Mar 31, 2026 | -87,442.99 |
| Dec 31, 2025 | 7.56 Mn |
| Dec 31, 2025 | 7.56 Mn |
| Sep 30, 2025 | -99,314.74 |
| Sep 30, 2025 | -99,314.74 |
| Jun 30, 2025 | -112,977.50 |
| Jun 30, 2025 | -112,977.50 |
| Mar 31, 2025 | 28.41 Mn |
| Mar 31, 2025 | 28.41 Mn |
| Dec 31, 2024 | 723,002.03 |
| Dec 31, 2024 | 723,002.03 |
| Sep 30, 2024 | -106,628.33 |
| Sep 30, 2024 | -106,628.33 |
| Jun 30, 2024 | -115,600.65 |
| Jun 30, 2024 | -115,600.65 |
| Mar 31, 2024 | -93,107.72 |
| Mar 31, 2024 | -93,107.72 |
| Dec 31, 2023 | -102,107.77 |
| Dec 31, 2023 | -102,107.77 |